Please use this identifier to cite or link to this item:
Title: Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Austin Authors: Crosswell, Howland E;LaCasce, Ann S;Bartlett, Nancy L;Straus, David J;Savage, Kerry J;Zinzani, Pier Luigi;Collins, Graham P;Fanale, Michelle;Fenton, Keenan;Dong, Cassie;Miao, Harry;Grigg, Andrew P 
Affiliation: Bon Secours Hematology and Oncology, Bon Secours, St. Francis Health System, Greenville, SC.
Dana-Farber Cancer Institute, Partners Cancer Care, Boston, MA.
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO.
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
British Columbia Cancer Agency, Vancouver, BC.
IRCCS University Hospital of Bologna, Institute of Hematology "Seràgnoli," Bologna, Italy; Department of Specialized Medicine, Diagnostic and Experimental, University of Bologna, Bologna.
Oxford University Hospitals NHS Foundation Trust, Oxford.
Seagen Inc., Bothell, WA.
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA.
Clinical Haematology
Issue Date: 5-Oct-2023
Date: 2023
Publication information: Haematologica 2023-10-05
Abstract: Not available.
DOI: 10.3324/haematol.2023.283303
Journal: Haematologica
PubMed URL: 37794803
ISSN: 1592-8721
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.